利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

27 条记录 (耗时 0.026 秒)

    Large Animal Model for Human-Like Advanced Atherosclerotic Plaque
    2.
    发明申请
    Large Animal Model for Human-Like Advanced Atherosclerotic Plaque 审中-公开
    人类先进动脉粥样硬化斑块的大动物模型

    公开(公告)号：US20100124533A1

    公开(公告)日：2010-05-20

    申请号：US12274817

    申请日：2008-11-20

    申请人： Stefan Tunev ,  Ankit Shah ,  Alejandra Caceres ,  Ya Guo ,  Julie Trudel ,  Phean Him ,  Ayala Hezi-Yamit

    发明人： Stefan Tunev ,  Ankit Shah ,  Alejandra Caceres ,  Ya Guo ,  Julie Trudel ,  Phean Him ,  Ayala Hezi-Yamit

    IPC分类号： A61B10/00 ,  A01K67/00

    CPC分类号： A01K67/027 ,  A01K2217/00 ,  A01K2227/108 ,  A01K2267/03 ,  A01K2267/0375

    摘要： An animal model for cardiovascular disease comprising one or more vascular plaque lesions formed at selected sites within a vascular segment of a nonhuman mammal. The vascular plaque lesion is formed by administering a hypercholesterolemic diet to the nonhuman mammal, inflicting an injury to the vascular wall at the selected site after a predetermined exposure to the hypercholesterolemic diet, and applying a hydrogel to the injured vascular wall. Another aspect of the invention provides a method for evaluating a test compound for an effect on atherosclerotic lesion formation comprising administering to a nonhuman mammal a hypercholesterolemic diet, and, after a defined period of time, isolating a segment of a blood vessel using a balloon catheter, inflicting an injury to the vascular wall within the isolated segment, and applying a hydrogel within the vascular segment. The method further comprises forming a vascular plaque lesion on the vascular wall at the site of the injury, delivering the test compound to the nonhuman mammal, and monitoring atherosclerotic lesion size and composition at the injured site after a defined period of exposure to the test compound.

    摘要翻译： 一种用于心血管疾病的动物模型，其包含在非人哺乳动物的血管片段内的选定位置处形成的一个或多个血管斑块损伤。 通过向非人哺乳动物施用高胆固醇血症饮食来形成血管斑块损伤，在预先暴露于高胆固醇血症饮食之后对选定部位的血管壁施加损伤，并将水凝胶施加到损伤的血管壁。 本发明的另一方面提供了一种用于评估对动脉粥样硬化病变形成的影响的测试化合物的方法，包括向非人类哺乳动物施用高胆固醇血症饮食，并且在限定的时间段之后，使用气囊导管分离血管的一段 对隔离区段内的血管壁造成损伤，并在血管段内施用水凝胶。 该方法还包括在损伤部位的血管壁上形成血管斑块损伤，将测试化合物递送至非人类哺乳动物，并在暴露于测试化合物的确定的时间段后监测受伤部位的动脉粥样硬化病变大小和组成 。

    Combination Local Delivery Using a Stent
    4.
    发明申请
    Combination Local Delivery Using a Stent 审中-公开
    组合使用支架本地交付

    公开(公告)号：US20100092534A1

    公开(公告)日：2010-04-15

    申请号：US12249576

    申请日：2008-10-10

    申请人： Ayala Hezi-Yamit ,  Iskender Matt Bilge ,  Jennifer Wong ,  Carol Sullivan ,  Natividad Vasquez

    发明人： Ayala Hezi-Yamit ,  Iskender Matt Bilge ,  Jennifer Wong ,  Carol Sullivan ,  Natividad Vasquez

    IPC分类号： A61F2/04 ,  A61K31/58 ,  A61K31/4355

    CPC分类号： A61L31/10 ,  A61L31/16 ,  A61L2300/222 ,  A61L2300/416 ,  A61L2300/45

    摘要： Described herein are implantable medical devices useful in treating vascular conditions such as restenosis. In one embodiment, stents are described in which a combination of bioactive agents is described for local delivery in the vasculature. The combination of bioactive agents comprises at least one compound capable of inhibiting smooth muscle cell proliferation and at least one compound capable of mitigating MCP- and/or TF induction. For example, a compound capable of inhibiting smooth muscle cell proliferation is a mTOR inhibitor and a compound capable of mitigating MCP-1 and/or TF induction is a corticosteroid.

    摘要翻译： 本文描述了可用于治疗诸如再狭窄的血管病变的可植入医疗装置。 在一个实施方案中，描述了支架，其中描述了生物活性剂的组合用于脉管系统中的局部递送。 生物活性剂的组合包含至少一种能够抑制平滑肌细胞增殖的化合物和至少一种能够减轻MCP-和/或TF诱导的化合物。 例如，能够抑制平滑肌细胞增殖的化合物是mTOR抑制剂，能够缓解MCP-1和/或TF诱导的化合物是皮质类固醇。

    Medical devices to treat or inhibit restenosis
    5.
    发明申请
    Medical devices to treat or inhibit restenosis 审中-公开
    用于治疗或抑制再狭窄的医疗器械

    公开(公告)号：US20070142905A1

    公开(公告)日：2007-06-21

    申请号：US11567821

    申请日：2006-12-07

    申请人： Ayala Hezi-Yamit ,  Carol Sullivan ,  Jennifer Wong

    发明人： Ayala Hezi-Yamit ,  Carol Sullivan ,  Jennifer Wong

    IPC分类号： A61F2/02 ,  A61F2/82

    CPC分类号： A61L27/54 ,  A61L27/34 ,  A61L29/085 ,  A61L29/16 ,  A61L31/10 ,  A61L31/16 ,  A61L2300/416 ,  A61L2300/436

    摘要： Implantable medical devices having anti-restenotic coatings are disclosed. Specifically, implantable medical devices having coatings of certain NF-kappaB inhibitors, particularly certain dialkyl fumarates, are disclosed. Dimethyl fumarate is a particularly preferred dialkyl fumarate. The anti-restenotic medical devices include stents, catheters, micro-particles, probes and vascular grafts. Intravascular stents are preferred medical devices. The medical devices can be coated using any method known in the art including compounding the dialkyl fumarate with a biocompatible polymer prior to applying the coating. Moreover, medical devices composed entirely of biocompatible polymer-dialkyl fumarate blends are disclosed. Additionally, medical devices having a coating comprising at least one dialkyl fumarate in combination with at least one additional therapeutic agent are also disclosed. Furthermore, related methods of using and making the anti-restenotic implantable devices are also disclosed.

    摘要翻译： 公开了具有抗再狭窄涂层的可植入医疗装置。 具体地，公开了具有某些NF-κB抑制剂，特别是某些二烷基富马酸盐的包衣的可植入医疗器械。 富马酸二甲酯是特别优选的富马酸二烷基酯。 抗再狭窄医疗器械包括支架，导管，微粒，探针和血管移植物。 血管内支架是优选的医疗装置。 可以使用本领域已知的任何方法涂覆医疗装置，包括在施加涂层之前将富马酸二烷基酯与生物相容性聚合物混合。 此外，公开了完全由生物相容性聚合物 - 富马酸二烷基酯混合物组成的医疗装置。 此外，还公开了具有包含至少一种富马酸二烷基酯与至少一种另外的治疗剂组合的涂层的医疗装置。 此外，还公开了使用和制备抗再狭窄植入式装置的相关方法。

    Method and Device for Localized Administration of Calcium Chelating Agent
    8.
    发明申请
    Method and Device for Localized Administration of Calcium Chelating Agent 审中-公开
    局部给药钙螯合剂的方法和装置

    公开(公告)号：US20100280595A1

    公开(公告)日：2010-11-04

    申请号：US12769803

    申请日：2010-04-29

    申请人： Iskender Bilge ,  Joseph Berglund ,  Ayala Hezi-Yamit

    发明人： Iskender Bilge ,  Joseph Berglund ,  Ayala Hezi-Yamit

    IPC分类号： A61L27/54 ,  A61M25/00 ,  A61F2/82 ,  A61M25/10 ,  A61F2/84

    CPC分类号： A61M25/104 ,  A61B2017/22098 ,  A61L29/16 ,  A61L31/16 ,  A61L2300/422 ,  A61L2300/622 ,  A61L2430/36

    摘要： A system for treating atherosclerotic cardiovascular disease and cardiac valve dysfunction comprises delivering one or more calcium chelating agents locally to a treatment site. One aspect of the invention provides a method including delivering a nano-particulate calcium chelating agent into a vascular wall. Another aspect of the invention provides a method and device for forming a sealed chamber around a cardiac valve, releasing one or more calcium chelating agents into the sealed chamber and decalcifying a cardiac valve in need thereof.

    摘要翻译： 用于治疗动脉粥样硬化性心血管疾病和心脏瓣膜功能障碍的系统包括将一种或多种钙螯合剂局部递送至治疗部位。 本发明的一个方面提供了一种包括将纳米颗粒钙螯合剂递送到血管壁中的方法。 本发明的另一方面提供了一种用于在心脏瓣膜周围形成密封腔的方法和装置，将一种或多种钙螯合剂释放到密封室中并对需要的心脏瓣膜进行脱钙。

    Local Delivery of Matrix Metalloproteinase Inhibitors
    10.
    发明申请
    Local Delivery of Matrix Metalloproteinase Inhibitors 审中-公开
    基质金属蛋白酶抑制剂的局部递送

    公开(公告)号：US20090299466A1

    公开(公告)日：2009-12-03

    申请号：US12131652

    申请日：2008-06-02

    申请人： Ayala Hezi-Yamit

    发明人： Ayala Hezi-Yamit

    IPC分类号： A61F2/82

    CPC分类号： A61F2/82 ,  A61F2250/0067 ,  A61L31/10 ,  A61L31/16 ,  A61L2300/432 ,  A61L2300/606

    摘要： Disclosed are medical devices and methods for the local delivery and treatment of vascular conditions. The methods and treatments involve local delivery of at least one matrix metalloproteinase inhibitor. The vascular conditions described herein include plaque rupture, aneurysm, stenosis, restenosis, atherosclerosis and combinations thereof.

    摘要翻译： 公开了用于局部输送和治疗血管状况的医疗装置和方法。 所述方法和治疗涉及至少一种基质金属蛋白酶抑制剂的局部递送。 本文所述的血管病症包括斑块破裂，动脉瘤，狭窄，再狭窄，动脉粥样硬化及其组合。